NCT06665178 - Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

December 1, 2028

Conditions

Breast Cancer

Interventions

DRUG

Sacituzumab Govitecan

Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.

Trial Locations (1)

V5Z4E6

RECRUITING

BC Cancer - Vancouver Center, Vancouver